Dato-DXd
Breast Cancer
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: The sequential multiple assignment randomized I-SPY2.2 phase 2 trial
Shatsky RA, Trivedi MS, Yau C, et al.
Nat Med. 2024;30(12):3737-3747. doi: 10.1038/s41591-024-03267-1.
Other/Multi
Other/Multi
Decoding clinical trial jargon: Helping people understand the efficacy end points used in cancer trials
Henley M, DeCotiis G, FitzGibbon H, Singhi EK
Future Oncol. 2025;21(1):11-14. doi: 10.1080/14796694.2024.2433411.
Dato-DXd
Breast Cancer
TROPION-Breast04: A randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naïve early-stage triple negative or HR-low/HER2− breast cancer
McArthur HL, Tolaney SM, Dent R, et al.
Ther Adv Med Oncol. 2025 Feb;17:17588359251316176. doi: 10.1177/17588359251316176.
Edoxaban
Cardiovascular - VTE
Treatment of venous thromboembolism with edoxaban over 18 months: Results from ETNA-VTE Europe
Agnelli G, Hoffmann U, Hainaut P, et al.
Thromb Haemost. 2025. doi: 10.1055/a-2497-4089.
Edoxaban
Cardiovascular - AF
Epistaxis versus nonepistaxis bleeding in anticoagulated patients with atrial fibrillation: Results from the ENGAGE AF-TIMI 48 trial
Semco RS, Bergmark RW, Murphy SA, et al.
J Am Heart Assoc. 2025 Jan;14(2):e031434. doi: 10.1161/JAHA.123.031434.
T-DXd
Breast Cancer
Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer: A plain language summary of the DESTINY-Breast04 study
Modi S
Future Oncol. 2025:1-14. doi: 10.1080/14796694.2024.2434388.
Edoxaban
Cardiovascular - AF
Two-year clinical outcomes of Taiwanese and other Asian ethnicities with atrial fibrillation treated with edoxaban in the ETNA-AF Asia registry
Wang C-C, Cheng C-I, Ueng K-C, et al.
J Arrhythm. 2025;41(1):e13212. doi: 10.1002/joa3.13212.
HER3-DXd, T-DXd
Breast Cancer
HER2 and HER3 expression during neoadjuvant treatment of HER2-negative early breast cancer: Potential for biomarker-driven sequencing of T-DXd and HER3-DXd
Singer CF, Jahn SW, Hlauschek D, et al.
Cancer Commun (Lond). 2025. doi: 10.1002/cac2.12657.
Dato-DXd
Lung Cancer
Datopotamab deruxtecan in advanced or metastatic non-small cell lung cancer with actionable genomic alterations: Results from the phase II TROPION-Lung05 study
Sands J, Ahn M-J, Lisberg A, et al.
J Clin Oncol. 2025 Apr;43(10):1254-1265. doi: 10.1200/JCO-24-01349.
T-DXd
Gastric Cancer
The tumor immune microenvironment and therapeutic efficacy of trastuzumab deruxtecan in gastric cancer
Koganemaru S, Koyama S, Suto F, et al.
Cancer Res Commun. 2025;5(1):84-93. doi: 10.1158/2767-9764.CRC-24-0302.
Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29